Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
Journal article published in 2017 by
Tobias Meißner,
Adam Mark,
Casey Williams,
Stephanie Wiebe,
Andrea Kerkhoff,
Eva Wardelmann,
Timo Gaiser,
Wolfgang E. Berdel,
Carsten Müller-Tidow,
Philip Rosenstiel,
Brian Leyland-Jones,
Andre Franke,
Norbert Arnold,
Martin Stanulla,
Michael Forster 
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Data provided by 